Rocket Pharmaceuticals (RCKT) Receivables - Net (2020 - 2023)

Rocket Pharmaceuticals has disclosed Receivables - Net across 4 years of filings, most recently posting $50000.0 for Q4 2023.

• Receivables - Net for Q4 2023 came in at $50000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $50000.0 (changed N/A YoY), and the FY2023 annual result was $50000.0, changed N/A from the prior year.
• Receivables - Net came in at $50000.0 for Q4 2023 at Rocket Pharmaceuticals, down from $900000.0 in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $1.6 million in Q2 2020 to a low of $50000.0 in Q4 2023.
• The 4-year median for Receivables - Net is $900000.0 (2020), against an average of $678571.4.
• Across the five-year window, Receivables - Net slumped 93.75% in 2021 and surged 800.0% in 2022, its largest moves.
• Rocket Pharmaceuticals' Receivables - Net stood at $900000.0 in 2020, then plunged by 88.89% to $100000.0 in 2021, then soared by 800.0% to $900000.0 in 2022, then sank by 94.44% to $50000.0 in 2023.
• The last three Receivables - Net figures came in at $50000.0 (Q4 2023), $900000.0 (Q1 2022), and $100000.0 (Q2 2021), per Business Quant data.